Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
3.130
+0.100 (3.30%)
At close: Apr 28, 2026, 4:00 PM EDT
3.000
-0.130 (-4.15%)
Pre-market: Apr 29, 2026, 4:00 AM EDT

Xenetic Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-2.68-3.96-4.13-6.55-5.65
Upgrade
Depreciation & Amortization
---0.030.04
Upgrade
Asset Writedown & Restructuring Costs
---1.79-
Upgrade
Stock-Based Compensation
0.060.170.280.510.41
Upgrade
Change in Accounts Payable
0.070.08-0.26-0.350.46
Upgrade
Change in Other Net Operating Assets
0.260.890-0.080
Upgrade
Operating Cash Flow
-2.29-2.82-4.11-4.65-4.74
Upgrade
Sale (Purchase) of Intangibles
----0.5-
Upgrade
Investing Cash Flow
----0.5-
Upgrade
Issuance of Common Stock
4---11.45
Upgrade
Financing Cash Flow
4---11.45
Upgrade
Net Cash Flow
1.72-2.82-4.11-5.156.72
Upgrade
Free Cash Flow
-2.29-2.82-4.11-4.65-4.74
Upgrade
Free Cash Flow Margin
-76.83%-112.69%-161.98%-272.23%-408.21%
Upgrade
Free Cash Flow Per Share
-1.34-1.83-2.69-3.27-4.61
Upgrade
Levered Free Cash Flow
-1.38-2.19-2.85-4.56-2.29
Upgrade
Unlevered Free Cash Flow
-1.38-2.19-2.85-4.56-2.29
Upgrade
Change in Working Capital
0.330.97-0.26-0.430.46
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.